HROW
HARROW, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$29.99
+2.04%Year over year
Reported trailing growth
- Revenue
- +21.1%
- EBITDA
- -64.4%
- EBIT
- -60.4%
- EPS
- —
- Free cash flow
- +116.5%
- Operating cash flow
- +54.9%
Forward estimates
Based on analyst estimates
- Revenue
- +75.2%
- EBITDA
- +1225.4%
- EPS
- +267.8%
Three-year CAGR
- Revenue
- +45.4%
- EBITDA
- +79.0%
- EBIT
- +172.0%
- Net income
- +70.6%
- EPS
- +71.4%
- Free cash flow
- +170.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026